For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and Tafamidis meglumine represents a true change. These groundbreaking therapies preserve the transthyretin protein, halting its damaging build-up and reducing the burden of the di